Biotransformation of tamoxifen in a human endometrial explant culture model

Chemico-Biological Interactions

Volumn 146, Issue 3, 2003, Pages 237-249

  Sharma, Minoti ^a   Shubert, David E ^b   Sharma, Moheswar ^a   Lewis, Jennifer ^a   McGarrigle, Barbara P ^b   Bofinger, Diane P ^b   Olson, James R ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Cytochrome P 450; Explant culture; Human endometrium; Tamoxifen biotransformation

Indexed keywords

4 HYDROXYTAMOXIFEN; ALPHA HYDROXYTAMOXIFEN; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DRUG METABOLITE; NORTAMOXIFEN; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CELL CULTURE; CELL LYSATE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG TRANSFORMATION; ENDOMETRIUM; EXPLANT; FLUORESCENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INCUBATION TIME; METABOLITE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TISSUE SECTION; TISSUE SPECIFICITY;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0345724797     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2003.06.002     Document Type: Article

References (45)

1. Colacurci N., De Seta L., De Franciscis P., Mele D., Fortunato N., Cassese S. Tamoxifen effects on endometrium. Panminerva Med. 42:2000;45-47.
2. Czernobilsky B., Lifschitz-Mercer B. Endometrial pathology. Curr. Opin. Obstet. Gynecol. 9:1997;52-56.
3. Mantyla E., Karlsson S., Nieminen L. Induction of endometrial cancer by tamoxifen in the rat. Li J.J., Li S.A., Gustafsson J.A., Nandi N., Sekely L.I. Hormonal Carcinogenesis. II:1996;442-445 Springer, New York.
4. Hirsimaki P., Hirsimaki Y., Nieminen L., Karlsson S., Mantyla E. On the safety studies of the antiestrogens toremifene and tamoxifen. Scand. J. Lab. Anim. Sci. 23:1996;147-153.
5. Gamboa da Costa G., McDaniel-Hamilton L.P., Heflich R.H., Marques M.M., Beland F.A. DNA adduct formation and mutant induction in Sprague-Dawely rats treated with tamoxifen and its derivatives. Carcinogenesis. 22:2001;1307-1327.
6. Osborne M.R., Hewer A., Hardcastle I.R., Carmichael P.L., Phillips D.H. Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res. 56:1996;66-71.
7. Carmichael P.L., Ugwumadu A.H., Neven P., Hewer A.J., Poon G.K., Phillips D.H. Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res. 56:1996;1475-1479.
8. 32P-postlabelling for tamoxifen DNA adducts in the human endometrium. Carcinogenesis. 20:1999;339-342.
9. Shibutani S., Suzuki N., Terashima I., Sugarman S.M., Grollman A.P., Pearl M.L. Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen. Chem. Res. Toxicol. 12:1999;646-653.
10. Shibutani S., Ravindernath A., Suzuki N., Terashima I., Sugarman S.M., Grollman A.P., Pearle M.L. Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis. 21:2000;1461-1467.
11. Shibutani S., Dasaradhi L., Terashima I., Banoglu E., Duffel M.W. α-Hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase resulting in tamoxifen DNA adducts. Cancer Res. 58:1998;647-653.
12. Glatt H., Davis W., Meinl W., Hermersdorfer H., Venitt S., Phillips D.H. Rat, but not human, sulfotransferase activates a tamoxifen metabolite to produce DNA adducts and gene mutations in bacteria and mammalian cells in cultures. Carcinogenesis. 19:1998;1709-1713.
13. Shibutani S., Shaw P.M., Suzuki N., Dasaradhi L., Duffel M.W., Terashima I. Sulfation of α-hydroxytamoxifen catalyzed by human hydroxysteroid sulfotransferase results in tamoxifen-DNA adducts. Carcinogenesis. 19:1998;2007-2011.
14. Phillips D.H., Hewer A., Horton M.N., Cole K.J., Carmichael P.L., Davis W., Osborne M.R. N-demethylation accompanies α-hydroxylation in the metabolic activation of tamoxifen in rat liver cells. Carcinogenesis. 20:1999;2003-2009.
15. Potter G.A., McCague R., Jarman M. A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis. 15:1994;439-442.
16. Moorthy B., Sriram P., Pathak D.N., Bodell W.J., Randerath K. Tamoxifen metabolic activation: comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vivo. Cancer Res. 56:1996;53-57.
17. Pathak D.N., Pongracz K., Bodell W.J. Activation of 4-hydroxytamoxifen and the tamoxifen derivative metabolite E by uterine peroxidase to form DNA adducts: comparison with DNA adducts formed in the uterus of Sprague-Dawley rats treated with tamoxifen. Carcinogenesis. 17:1996;1785-1790.
18. Marques M.M., Beland F.A. Identification of tamoxifen-DNA adducts formed by 4-hydroxytamoxifen quinone methide. Carcinogenesis. 18:1997;1949-1954.
19. Dasaradhi L., Shibutani S. Identification of tamoxifen-DNA adducts formed by α-sulfate tamoxifen and α-acetoxytamoxifen. Chem. Res. Toxicol. 10:1997;189-196.
20. Sanchez C., Shibutani S., Dasaradhi L., Bolton J.L., Fan P.W., McClelland R.A. Lifetime and reactivity of an ultimate tamoxifen carcinogen: the tamoxifen carbocation. J. Am. Chem. Soc. 120:1998;13513-13514.
21. Lien E.A., Solheim E., Ueland P.M. Distribution of tamoxifen and its metabolites in rat and human tissue during steady state treatment. Cancer Res. 51:1991;4837-4844.
22. Hukkanen J., Mantyla M., Kangas L., Wirta P., Hakkola J., Paakki P., Evisalmi S., Pelkonen O., Raunio H. Expression of cytochrome P450 genes encoding enzymes active in the metabolism of tamoxifen in human uterine endometrium. Pharmacol. Toxicol. 82:1998;93-97.
23. Vadlamuri S.V., Glover D.D., Turner T., Sarkar M.A. Regiospecific expression of cytochrome P4501A1 and 1B1 in human uterine tissue. Cancer Lett. 122:1998;143-150.
24. Sarkar M.A., Vadlamuri V., Ghosh S., Glover D.D. Expression and cyclic variability of CYP3A4 and CYP3A7 isoforms in human endometrium and cervix during the menstrual cycle. Drug Metab. Dispos. 31:2001;1-6.
25. Osteen K.G., Rodgers W.H., Gaire M., Hargrove J.T., Gorstein F., Matrisian L.M. Stromal-epithelial interaction mediated steroidal regulation of metalloproteinase expression in human endometrium. Proc. Natl. Acad. Sci. USA. 91:1994;10129-10133.
26. Bofinger D.P., Feng L., Chi L.H., Love J., Stephen F.D., Sutter T.R., Osteen K.G., Costich T.G., Batt R.E., Koury S.T., Olson J.R. Effect of TCDD exposure on CYP1A1 and CYP1B1 in explant cultures of human endometrium. Toxicol. Sci. 62:2001;299-314.
27. Merle O., Guitton J., Burke M.D., Ollangnier M. Rapid and simple method to determine tamoxifen and its major metabolites in human liver microsomes by high performance liquid chromatography with fluorescence detection. Anal. Lett. 31:1998;2067-2076.
28. Fried K.M., Wainer I.W. Direct determination of tamoxifen and its four major metabolites in plasma using coupled column high-performance metabolites in plasma using coupled column high-performance liquid chromatography. J. Chromatogr. B. 655:1994;261-268.
29. Sharma M. Analysis of tamoxifen-DNA adducts by high-performance liquid chromatography using postcolumn online photochemical activation. Biochem. Biophys. Res. Commun. 273:2000;40-44.
30. Foster A.B., Jarman M., Leung O.-T., McCague R., Leclercq G., Devleeschouwer N. Hydroxy derivatives of tamoxifen. J. Med. Chem. 28:1985;1491-1497.
31. Brown K., Heydon R.T., Jukes R., White I.N., Martin E.A. Further characterization of the DNA adducts formed in rat liver after the administration of tamoxifen, N-desmethyltamoxifen or N,N-didesmethyltamoxifen. Carcinogenesis. 20:1999;2011-2066.
32. Drahushuk A.T., McGarrigle B.P., Tai H.-L., Kitareewan S., Goldstein J.A., Olson J.R. Validation of precision-cut liver slices in dynamic organ culture as an in vitro model for studying CYP1A1 and CYP1A2 induction. Toxicol. Appl. Pharmacol. 140:1996;393-403.
33. 2+-sedimented microsomes from rat liver. Biochem. Pharmacol. 21:1972;3249-3256.
34. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
35. Laemmli V.K. Cleavage of structural protein during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
36. Dehal S.S., Kupfer D. Evidence that the catechol 3,4-dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins. Cancer Res. 56:1996;1283-1290.
37. Mani C., Kupfer D. Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation. Cancer Res. 51:1991;6052-6058.
38. Mani C., Pierce R., Parkinson A., Kupfer D. Involvement of cytochrome P-450 3A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis. 15:1994;2715-2720.
39. Giorda G., Franceschi L., Crivellari D., Magri M.D., Veronesi A., Scarabelli C., Furlanut M. Determination of tamoxifen and its metabolites in the endometrial tissue of long-term treated women. Eur. J. Cancer. 36:(Suppl. 4):2000;S88-S99.
40. Crew H.K., Ellis S.W., Lennard M.S., Tucker G.T. Variable contribution of cytochrome P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem. Pharmacol. 53:1997;171-178.
41. Dehal S.S., Kupfer D. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res. 57:1997;3402-3406.
42. Jacolot F., Simon I., Dreano Y., Beaune P., Riche C., Berthou F. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem. Pharmacol. 41:1991;1911-1919.
43. Boocock D.J., Brown K., Gibbs A.H., Sanchez E., Turteltaub K.W., White I.N. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis. 23:2002;1897-1901.
44. Gamboa da Costa G., Hamilton L.P., Beland F.A., Marques M.M. Characterization of the major DNA adduct formed by α-hydroxy-N- desmethyltamoxifen in vitro and in vivo. Chem. Res. Toxicol. 13:2000;200-207.
45. Okubo T., Nagai F., Ushiyama K., Yokoyama Y., Ozawa S., Kano K., Tomita S., Kubo H., Kano I. DNA cleavage and 8-hydroxydeoxyguanosine formation caused by tamoxifen derivative in vitro. Cancer Lett. 122:1998;9-15.